WASHINGTON, D.C. — Federal health officials announced a new partnership with leading urology organizations aimed at expanding awareness and use of a treatment that researchers say can help prevent recurring urinary tract infections and other health problems in postmenopausal women.
What This Means for You
- Federal officials are promoting greater awareness of treatments for menopause-related urinary health problems.
- Doctors and patients will receive new education about local estrogen therapy for certain conditions.
- Health officials say the effort could help reduce repeated infections and unnecessary antibiotic use.
The U.S. Department of Health and Human Services said its Office on Women’s Health has signed a memorandum of understanding with the American Urological Association, the American Urological Education and Research organization, and the Urology Care Foundation.
The agreement focuses on improving awareness and education about the use of local estrogen therapy — a treatment applied directly to tissue — for postmenopausal women experiencing genitourinary syndrome of menopause and recurring urinary tract infections.
Genitourinary syndrome of menopause refers to a collection of symptoms affecting the urinary and reproductive systems after menopause, including vaginal dryness, urinary urgency, and discomfort caused by declining estrogen levels.
Education and Outreach Efforts Planned
Under the agreement, federal health officials and the urology organizations will share information, develop educational materials, and provide guidance to clinicians and patients nationwide.
“This collaboration represents an important step forward in addressing a significant and often undertreated women’s health concern,” said Dr. Dorothy A. Fink, principal deputy assistant secretary for health and director of the Office on Women’s Health.
“Many postmenopausal women are not aware that local estrogen therapy is a safe and effective treatment for GSM and recurrent UTIs,” Fink said. “By joining forces with the AUA, we can ensure that clinicians and patients alike have access to clear, evidence-based guidance.”
Health Risks Linked to Recurrent Infections
Health officials say hormonal changes after menopause can weaken tissues in the urinary and reproductive systems and alter natural bacterial balances.
These changes can increase the risk of urinary tract infections, which may lead to complications such as hospitalization, sepsis — a life-threatening bodywide response to infection — and repeated antibiotic use.
Officials say frequent antibiotic use can contribute to antimicrobial resistance, a growing public health concern in which infections become harder to treat.
Research cited by the department indicates that local estrogen therapy can help restore tissue health, rebalance protective bacteria, and lower the frequency of recurrent infections.
Potential Quality of Life Benefits
Health officials say treatment may also improve several symptoms commonly experienced during menopause.
These include urinary urgency, pelvic discomfort, pain during intercourse, and reduced sexual function.
Studies have shown that local estrogen therapy can improve lubrication, tissue elasticity, and overall urogenital health in postmenopausal women.
Partnership Timeline
The memorandum of understanding is expected to remain in effect for an initial one-year period and may be extended for up to five years.
During that time, federal officials and medical experts will work together to educate clinicians and patients about evidence-based treatment options and evaluate the program’s impact on public health outcomes.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.